Trastuzumab biosimilar - Hanwha Biologics

Drug Profile

Trastuzumab biosimilar - Hanwha Biologics

Alternative Names: HD 201

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Hanwha Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 13 Jan 2017 Prestige Biopharma plans a phase III trial for Breast cancer (Inoperable/unresectable, Combination therapy, Late-stage disease) in Ukraine, Belarus, Bulgaria, Estonia, Hong Kong, Latvia, Lithuania, Malaysia, Philippines, Russia, Singapore, Slovenia, Thailand, Slovakia (NCT03013504)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top